2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Abstract Full Text (PDF) All Versions of this Article: ASN.2005080799v1 17/1/150    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Timoshanko, J. R. Articles by Holdsworth, S. R. Search for Related Content PubMed PubMed Citation Articles by Timoshanko, J. R. Articles by Holdsworth, S. R.

A Pathogenetic Role for Mast Cells in Experimental Crescentic Glomerulonephritis

Centre for Inflammatory Diseases, Monash University, Department of Medicine, Monash Medical Centre, Clayton, Victoria, Australia

Address correspondence to: Dr. Jennifer Timoshanko, Monash University, Department of Medicine, Monash Medical Center, 246 Clayton Road, Melbourne, Victoria 3168, Australia. Phone: +61-3-9594-5549; Fax: +61-3-9594-6495; jennifer.timoshanko{at}med.monash.edu.au

Received for publication August 1, 2005. Accepted for publication October 11, 2005.

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Mast cells infiltrate kidneys of humans with crescentic glomerulonephritis (GN), and the degree of infiltrate correlates with outcome. However, a functional role for mast cells in the pathogenesis of GN remains speculative. GN was induced by intravenous administration of sheep anti-mouse glomerular basement membrane globulin. After 21 d, systemic immune responses and disease severity were analyzed in wild-type, mast cell–deficient (W/W^v), and bone marrow–derived mast cell–reconstituted W/W^v mice (BMMCW/W^v). There were no significant differences in the humoral response toward the nephritogenic antigen or in memory T cell number among the three groups; however, antigen-stimulated T cell IFN- production was significantly elevated in BMMCW/W^v mice. Dermal delayed-type hypersensitivity in W/W^v mice was reduced compared with wild-type and BMMCW/W^v mice. No mast cells were detected in kidneys of W/W^v mice with GN, whereas in BMMCW/W^v mice, the numbers of renal mast cells were similar to wild-type mice with GN. W/W^v mice were protected from the development of crescentic GN, exhibiting reduced crescent formation (10 ± 1% c.f. 36 ± 2% in wild type), glomerular influx of T cells/macrophages, and interstitial infiltrate compared with wild-type mice. In contrast, BMMCW/W^v demonstrated a similar severity of GN as wild-type mice (35 ± 2% crescentic glomeruli), accompanied by a prominent inflammatory cell infiltrate into glomeruli and interstitial areas. Glomerular expression of intercellular adhesion molecule-1 and P-selectin were reduced in W/W^v mice but restored to wild-type levels in BMMCW/W^v mice. These findings suggest that renal mast cells mediate crescentic GN by facilitating effector cell recruitment into glomeruli via augmentation of adhesion molecule expression.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Mast cells are critical effector cells of both innate and adaptive immunity (1). Their major role in disease was originally described as the major effector cell in the pathogenesis of allergic reactions (2). Mast cells derive from committed bone marrow precursors that migrate to peripheral tissues, where they fully mature into phenotypically distinct mast cells (3). Two phenotypically distinct mast cell populations have been described in humans on the basis of their neutral protease composition: The MC_T (containing tryptase) and the MC_TC (containing tryptase and chymase). In rodents, two distinct subpopulations of mast cells also exist: Connective tissue–type mast cells (CTMC) and the mucosal tissue–type mast cells (MMC). These populations differ in staining characteristics, size, mediator content, and T cell dependency; it is proposed that MC_TC are like CTMC, whereas MC_T are similar to MMC (4). Mast cells are located predominantly in the perivascular connective tissues of multiple organs (skin, lung, heart, intestine spleen, lymph nodes, and peritoneum) (5). Their numbers increase at sites of tissue injury and inflammation, where they regulate both inflammatory responses and tissue repair (6–9).

Mast cells play a major role in mediating both normal immunity and autoimmune responses in human inflammatory disease. Conclusive evidence of the capacity for mast cells to govern the pathologic inflammatory response stems from a special strain of mouse with stem cell factor (SCF)-receptor mutations, resulting in the absence of tissue mast cells: WBB6/F₁-Kit^W/Kit^Wv (W/W^v). Studies in experimental autoimmune encephalomyelitis (10), adjuvant induced vasculitis (11), asthma (12), and arthritis (13) have reported a significant reduction in disease incidence and severity in W/W^v mice, when compared with wild-type (WT) littermate controls. Moreover, the selective engraftment of mast cells in W/W^v mice restored disease severity, confirming the requirement of mast cell participation in a variety of immune-driven inflammatory conditions (10,12).

The phenomenon of mast cell accumulation in the renal interstitium of patients with various nephropathies (14–17), including diabetic nephropathy, chronic glomerulonephritis (GN), renal vasculitis, lupus nephritis, acute cellular rejection of renal allografts, IgA nephritis, and crescentic GN (18,19), has been widely demonstrated. Mast cells release a broad range of mediators upon activation: Preformed granule mediators (tryptase, chymase, histamine, and heparin), lipid-derived mediators (leukotrienes), and chemokines. Mast cells also produce a variety of cytokines that mediate delayed-type hypersensitivity (DTH) (9) and are key components of the pathogenesis of proliferative GN, injurious (e.g., TNF), and protective (e.g., IL-4) (20–22). Experimental and human GN studies have demonstrated a strong correlation between the number of interstitial mast cells and severity of interstitial injury (19,23–25). In inflammatory renal injury induced in rats by subtotal nephrectomy, a significant infiltration of mast cells in the tubulointerstitium was accompanied by increased IL-8, SCF, and TGF- expression (26).

Although these histologic studies suggest a temporal relationship between mast cell infiltration and the development of renal injury, in vivo studies are required to prove a functional relationship. Two recent studies of mast cell–deficient rodents do not support a significant pathogenic role for mast cells in GN. In pristane-induced experimental lupus nephritis, mast cell–deficient mice developed equivalent renal disease to WT mice (27). A slightly protective role for mast cells in the development of fibrosis was suggested in rats 6 wk after the induction of puromycin aminonucleoside nephritis (28). A functional role of mast cells in the pathogenesis of crescentic GN has not been established. In these studies, we assessed the development of crescentic GN in W/W^v, WT congenic littermates, and bone marrow–derived mast cell (BMMC)-engrafted W/W^v mice. We used a well-characterized model of murine crescentic GN induced by a planted foreign antigen (Ag), in which crescentic injury is a manifestation of a T helper cell 1 (Th1)-directed DTH-mediated immune response that is dependent on effector CD4+ T cells (29–32). We demonstrate a nonredundant role for mast cells in adhesion molecule expression, infiltration of glomeruli and interstitial areas with leukocytes, and crescent formation during the course of crescentic GN.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Mice
Male WBB6/F₁-Kit^W/Kit^Wv (W/W^v) mice and their congenic WT littermates (+/+) were purchased from The Jackson Laboratory (Bar Harbor, ME). These mice were housed in a viral room facility at Monash Medical Centre, Monash University, and monitored daily. All animal procedures were approved by the Monash Medical Centre Animal Ethics Committee B.

Mast Cell Preparation and Reconstitution
BMMC Differentiation and Cell Transfer into W/W^v.
The standard technique of reconstituting the mast cell population in W/W^v mice relies on in vitro differentiation of mast cells (10,33). BMMC were differentiated in culture from bone marrow cells that were harvested from 6- to 8-wk-old WT mice. Mice were killed, and the femora and tibiae were flushed with serum-free RPMI 1640 medium. Resulting cells were cultured in medium that consisted of RPMI 1640, 15% heat-inactivated FBS, 50 U/ml penicillin, 50 µg/ml streptomycin, 2 mM l-glutamine, 1 mM sodium pyruvate, 50 µm 2-mecrapoethanol (2-ME), 25% WEHI-3 supernatant, and 12.5 ng/ml recombinant murine (rm) SCF (R&D Systems, Gymea, NSW, Australia). Nonadherent cells were transferred to fresh culture medium once per week. After 4 to 6 wk of culture, the purity of mast cells was determined by flow cytometry for c-kit⁺ and FCRI⁺ expression. Fc receptors were blocked with rat anti-mouse CD16/32 (FcIII/II receptor) mAb mouse (BD Fc Block; BD Biosciences PharMingen, San Diego, CA), and cells subsequently were incubated with murine IgE (10 µg/ml; BD Biosciences PharMingen) for 50 min at 4°C. Bound IgE was detected by addition of rat anti-mouse IgE-FITC (R35–72; BD Biosciences PharMingen), and c-kit expression was determined using rat anti-mouse c-kit-PE (2B8; BD Biosciences PharMingen). More than 95% of cells were positive for both IgE and c-kit and were considered to be mast cells.

Reconstitution of Mast Cells in W/W^v-Deficient Mice
BMMC (5 x 10⁶) in 300 µl of sterile saline were injected via the tail vein into 9- to 10-wk-old W/W^v mice; mice were housed for 8 wk before being subjected to GN disease induction. For verifying mast cell reconstitution, small intestine, skin, and kidneys were harvested and fixed in either 4% paraformaldehyde (6 h) or Carnoy’s solution (60% ethanol, 30% chloroform, 10% acetic acid; 4 h).

Paraformaldehyde-fixed tissues were frozen in OCT and cryostat sectioned (6 µm), whereas, Carnoy’s-fixed tissues were paraffin embedded. For quantification of MMC, 5-µm sections from Carnoy’s-fixed tissues were stained with Alcian blue/Safranin O (Sigma Aldrich Pty Ltd, Castle Hill, Australia) or acidified toluidine blue (Sigma Aldrich Pty Ltd) and examined under light microscopy at x400 magnification. Acidified toluidine blue was effective in demonstrating mast cells in skin and intestine but failed to demonstrate renal mast cells. However, occasional mast cells could be demonstrated using Alcian blue/Safranin O. For assessment of whether mast cells contained significant amounts of heparin, 4 µm of Carnoy’s-fixed (deparaffinized) and 6 µm of snap-frozen (air dried) sections were fixed for 15 min in ethanol/acetic acid (3:1) and rinsed in 100% ethanol (15 min) followed by a 10-min wash in distilled water before staining for 20 min with 0.02% (wt/vol) berberine sulfate (Sigma Aldrich Pty Ltd) in water (pH 4 with 1% citric acid). Slides were rinsed briefly in distilled water (pH 4.0), air dried, mounted with glycerol, and examined immediately with a fluorescence microscope (34). Berberine sulfate–positive cells exhibited a bright yellow fluorescence. In a blinded manner, we counted the number of positive cells per high-power field (hpf).

Initiation of GN and Experimental Design
Sheep anti-mouse glomerular basement membrane (GBM) globulin was prepared as described previously (35). Nonaccelerated autologous-phase anti-GBM GN was induced in 16- to 17-wk-old W/W^v (n = 8), W/W^vBMMC (n = 8) and +/+ (n = 8) mice by intravenous injection of 7.2 mg of anti-GBM globulin in divided doses 3 h apart (total dose = 14.4 mg). Renal injury was assessed 21 d after anti-GBM Ab administration. Results are expressed as the mean ± SEM. The statistical significance of differences between the groups was determined by one-way ANOVA, followed by Newman-Keuls post hoc test (GraphPad Prism; GraphPad Software Inc., San Diego, CA).

Assessment of Systemic Immune Responses
Humoral Immune Responses to Sheep Globulin.
Total serum anti-sheep globulin Ig and anti-sheep globulin IgG1, IgG2a, IgG2b, and IgG3 isotypes were measured by ELISA on serum that was collected at the end of the experiment. Assays were performed using microtiter plates that were coated with sheep globulin at a concentration of 10 µg/ml, with 3,3'5,5' tetramethyl-benzidine (Sigma Aldrich Pty Ltd) added as the chromogenic substrate; the absorbance was read at 450 nm, as described previously (36).

Induction of Dermal DTH to Sheep Globulin.
All mice that developed GN were challenged 24 h (day 20) before the end of the experiment by intradermal injection of 500 µg of sheep globulin in 50 µl of PBS into the right-hind plantar surface of the footpad. The same dose of an irrelevant Ag (horse globulin) was injected into the contralateral footpad. Swelling was measured after 24 h using a micrometer (Mitutoyo, Kawasaki-Shi, Japan). DTH was assessed as the difference in swelling between the two footpads and is expressed as mm.

Assessment of CD4⁺ T Cell Activation in the Spleen and Renal Lymph Node.
Single-cell suspensions were prepared from isolated spleens and draining renal lymph nodes. Cells were incubated with anti-CD44 and anti-CD4 antibodies (BD Biosciences PharMingen); flow cytometric analysis followed, accompanied by appropriate isotype controls. The percentage of activated CD4⁺ T cells was ascertained by the proportion of cells that were positive for both antibodies.

Assessment of Splenocyte IFN- Expression.
Spleens were removed aseptically, and single-cell suspensions were prepared in DMEM/5% FCS; splenocytes were incubated and cultured with sheep globulin as described previously (37). IFN- in resulting supernatants was measured by ELISA by using rat anti-mouse IFN- as the capture Ab (RA-6A2; BD Biosciences PharMingen) and biotinylated rat anti-mouse IFN- (XMG1.2; BD Biosciences PharMingen) as the capture Ab as described previously (38). The enzyme-linked immunospot assay was used to detect and enumerate individual cellular production of IFN- in vitro. The assay protocol was followed as outlined in the BD Biosciences instructions. Briefly, microwell plates were coated with anti-mouse IFN- (51–2525KC) in sterile PBS; microwells then were blocked with blocking solution (RPMI/10% FCS/1% PS/2-ME) and washed, and splenocytes were added (4 x 10⁶ in 100 µl) with Ag (normal sheep globulin) and incubated at 37°C for 24 h. After cells were aspirated, microwells were washed twice and the biotinylated detection Ab (biotinylated anti-mouse IFN-; 51–1818KZ; BD Biosciences) was added; avidin–horseradish peroxidase was applied after washing, the chromogenic substrate solution was applied, and the plate was air dried and protected from light until evaluated. Spots were enumerated manually with an inverted microscope; different sizes of spots were counted and assigned a value as follows: 1 = small, 2 = medium, and 3 = large. Results are expressed as area of positive staining/10⁶ CD4⁺ splenocytes.

Assessment of Renal Histology
Glomerular and Interstitial.
For assessment of glomerular crescent formation, kidney tissue was fixed in Bouin’s fixative and embedded in paraffin, and 3-µm sections were stained with Periodic Acid-Schiff reagent. Glomeruli were considered to exhibit crescent formation when two or more layers of cells were observed in Bowman’s space. A minimum of 50 glomeruli were assessed to determine the crescent score for each animal. The number of interstitial cells in Periodic Acid-Schiff–stained renal tissue sections was also assessed. Five randomly selected cortical areas, which excluded glomeruli, were counted for each animal using a 10-mm² graticule fitted in the eyepiece of the microscope. Each hpf represented an area of 1 mm². Data are expressed as cells/mm² and represent the mean ± SEM, and for assessment of the interstitium, four mice from each group were randomly selected.

Leukocyte Infiltration.
For determination of the extent of inflammatory cell influx into glomeruli, kidney tissue and spleen were fixed in periodate/lysine/paraformaldehyde. Six-micrometer cryostat-cut sections were stained to demonstrate CD4⁺ T cells and macrophages with mAb GK1.5 and M1/70, respectively, using a three-layer immunoperoxidase technique (39). A minimum of 20 equatorially sectioned glomeruli were assessed per animal, and results are expressed as cells per glomerular cross-section (gcs).

Renal Chemokine Expression
RNA Extraction.
Total kidney RNA was extracted with TRIzol reagent (Life Technologies, Victoria, Australia) according to the manufacturer’s protocol. The final product was air-dried and dissolved in DNase/RNase free water (Life Technologies) and stored at –70°C. The concentration of RNA was determined by spectroscopy at 260 nm.

RNAse Protection Assay.
Total kidney RNA was assessed by the RiboQuant system (BD Bioscience PharMingen) as previously reported (37). Image Gauge software (version 3.46; Fuji Photo Film, Tokyo, Japan) was used to evaluate the gel image. The expression of chemokines lymphotactin (LTN); regulated upon activation, normal T cell expressed and secreted (RANTES); macrophage inflammatory protein-1 (MIP-1); MIP-1; MIP-2; monocyte chemoattractant protein–1 (MCP-1); T cell activation–3 (TCA-3); and IFN-inducible protein–10 (IP-10) was measured and normalized to the housekeeping gene L32.

Functional Assessment of Renal Injury
Proteinuria.
Mice were housed individually in cages to collect urine before administration of anti-GBM globulin and over the final 24 h (day 20) of the experiment. Urinary protein concentrations were determined by a modified Bradford method. Before induction of GN, all groups of mice had 24-h urine protein excretion in the normal range (0.5 to 2.0 mg/24 h).

Serum Creatinine.
Serum creatinine concentrations were measured by an enzymatic creatininase assay.

Measurement of Urinary Nitric Oxide Levels
Concentrations of urinary nitrite plus nitrate were determined by Griess assay, as described previously (40); results are expressed as mg/ml.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Repopulation of Mast Cells with BMMC in W/W^v Mice
We performed mast cell reconstitution in 9- to 10-wk-old W/W^v recipients by intravenous injection of BMMC (determined to be >95% pure by flow cytometry). For assessment of reconstitution of mast cells in these mice, animals were killed at 11 wk after injection, and major organs (gut, skin, and spleen) and lymph nodes were examined using histochemistry and flow cytometry. Similar patterns of mast cells were observed using an Alcian blue/Safranin O protocol in the gut of both reconstituted and +/+ mice, and, as expected, no mast cells were observed in the W/W^v mice. Flow cytometry of splenocytes revealed a similar percentage of cells that co-expressed c-kit and FcR in BMMCW/W^v (12%) and +/+ (16%) mice. Thus, the mast cell population was present 11 wk posttransplantation of BMMC, similar to previously reported findings (10,33).

Immune Responses in W/W^v, BMMCW/W and +/+ Mice
Humoral immunity, measured by ELISA for total mouse anti-sheep globulin Ig in serum (Figure 1), was similar in all three groups; hence, mast cells are not required for the development of humoral immunity. Serum levels of nephritogenic Ag-specific (sheep globulin) IgG1, IgG2a, IgG2b, and IgG3 were determined by isotype-specific ELISA; there were no significant differences in IgG1, IgG2b, and IgG3 isotypes measured in the +/+, W/W^v, and BMMCW/W^v mice, although IgG2a was elevated in the BMMCW/W^v mice compared with +/+ mice. Cutaneous DTH to sheep globulin was significantly impaired in W/W^v mice compare with +/+ and BMMCW/W^v mice, which demonstrated similar swelling in response to sheep globulin. There was no difference in the percentage of CD4⁺ renal lymph node cells that expressed CD44, a marker for memory T cells. Finally, we assessed splenocyte production of IFN- and individual T cell production of IFN- in response to the nephritis-inducing Ag (sheep globulin; enzyme-linked immunospot). We found a reduction of IFN- production in W/W^v that was NS and a significant elevation of activated T cells expressing IFN- in BMMCW/W^v compared with +/+ and W/W^v mice.

View larger version (26K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 1. (A) Serum titers of mouse anti-sheep globulin Ig in wild-type, +/+, mast cell–deficient (W/Wv), and bone marrow–derived mast cell–reconstituted W/Wv (BMMCW/Wv) mice that developed crescentic glomerulonephritis (GN). (B) Graphical representation of the mean value ± SE of nephritogenic antigen (Ag)-specific (sheep-globulin) subclasses (IgG1, IgG2a, IgG2b, and IgG3) in serum, detected at a 1:100 dilution by ELISA. (C) Dermal delayed-type hypersensitivity responses to sheep globulin in +/+, W/Wv, and BMMCW/Wv mice with GN (21 d after intravenous injection of sheep globulin); each bar represents the mean value of the difference in swelling between the footpads. (D) The percentage of renal lymph node CD4+ T cells that expressed CD44 was not different in the three groups. (E) Graphical representation of the amount of IFN- (measured by ELISA) produced by splenocytes after a 72-h incubation with the nephritogenic Ag in +/+, W/Wv, and BMMCW/Wv mice with GN. (F) Individual splenocyte IFN- production in response to Ag was measured by enzyme-linked immunospot; the graph represents the area of IFN- corrected for the % of T cells in each well as determined by FACS (P < 0.05 c.f. +/+; •P < 0.05 c.f. BMMCW/Wv; P < 0.05 c.f. W/Wv).

View larger version (38K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 2. Representative pictures of berberine sulfate–positive mast cells in renal sections at x200 (A) and x400 (B) magnification. (C) A cropped and magnified image of a renal mast cell demonstrating a typical granular localization of heparin detected by berberine sulfate. (D) Berberine-positive mast cells in the interstitium were counted and expressed as number per high-power field (hpf), as graphed; no difference in renal mast cell number between +/+ and BMMCW/Wv mice was detected.

Crescentic GN in W/W^v Mice
To determine whether mast cells play a role in the development of crescentic GN, we compared the development of characteristic features (accumulation of DTH effectors, crescent formation, and renal injury) of disease in mast cell–deficient mice (W/W^v) and congenic littermates (+/+). Twenty-one days after induction of GN, glomerular crescent formation (Figure 3) was prominent in +/+ mice (36 ± 2% of glomeruli affected), with a significant inflammatory cell influx into the glomeruli (CD4⁺ T cells 1.6 ± 0.20 cells/gcs; macrophages 2.2 ± 0.22 cells/gcs) and interstitial inflammatory cellular infiltrate (192 ± 20 cells/mm²). A significant increase in the numbers of renal mast cells was observed in +/+ mice with GN. Nitric oxide, a product of activated macrophages, was elevated in urine from +/+ mice with GN (2.7 ± 0.4 nitrite mg/ml, normal 0.3 ± 0.1 mg/ml; Figure 4). Renal injury, indicated by proteinuria (5.0 ± 0.3 mg/24 h) and serum creatinine (15 ± 0.8 µmol/L), was significantly elevated in +/+ mice above values observed in normal mice (proteinuria 1.0 ± 0.2 mg/24 h; serum creatinine 9.8 ± 1.2 µmol/L).

View larger version (115K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 3. The histologic appearance of crescentic glomerular injury in +/+ (A), W/Wv (B), and BMMCW/Wv (C) mice 21 d after administration of sheep anti-mouse glomerular basement membrane (GBM) globulin. +/+ and BMMCW/Wv mice developed proliferative GN with glomerular crescent formation and abundant deposition of glomerular Periodic Acid-Schiff (PAS)-positive material. W/Wv mice displayed minor histologic changes with infrequent crescentic glomeruli. A prominent cellular infiltrate was observed in interstitial areas of +/+ (D) and BMMCW/Wv (F) mice; however, W/Wv mice displayed a reduced interstitial cellular infiltrate (E). Magnification, x400 in A through C (PAS stain); x200 in D through F (PAS stain).

View larger version (28K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 4. Assessment of the histologic features of glomerular injury in +/+, W/Wv, and BMMCW/Wv mice with GN. (A) +/+ mice with GN developed severe GN with a high incidence of glomerular crescent formation (36%). In contrast, W/Wv mice were protected from the development of severe crescentic GN with a significant reduction in the proportion of glomeruli affected (10%). Restoration of the mast cell population restored GN severity, with approximately 35% of crescentic glomeruli observed in BMMCW/Wv mice with GN. (B) Glomerular accumulation of CD4+ T cells was equivalent in +/+ and BMMCW/Wv mice but significantly reduced in W/Wv mice. (C) The interstitial cellular infiltrate in +/+, W/Wv and BMMCW/Wv mice with GN was quantified using a graticule; results are expressed as cells/mm2. W/Wv mice demonstrated a significant reduction in the number of cells present in the interstitium, whereas +/+ and BMMCW/Wv mice exhibited a prominent increase in interstitial inflammation. (D) Influx of macrophages into the glomerulus paralleled CD4+ T cell migration, as macrophage numbers were significantly reduced in W/Wv mice but not attenuated in +/+ and BMMCW/Wv mice (P < 0.05 c.f. +/+; •P < 0.05 c.f. BMMCW/Wv).

View larger version (20K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 5. Functional indices of renal injury and urinary nitric oxide in +/+, W/Wv, and BMMCW/Wv mice with GN. (A) We measured urinary nitric oxide levels by Griess assay and found an elevation of nitrite in the urine of +/+ mice with GN, whereas urinary nitrite levels in W/Wv and BMMCW/Wv mice with GN were significantly attenuated (the dotted line represents the nitric oxide level observed in urine of non-nephritic +/+ mice). (B) All three groups of mice with GN developed proteinuria in comparison with proteinuria observed in normal non-nephritic +/+ mice, represented by the dotted line. (C) Elevated serum creatinine demonstrated impaired renal function in +/+ and BMMCW/Wv mice, whereas significantly lower serum creatinine levels were demonstrated in W/Wv mice (the dotted line indicates normal serum creatinine in non-nephritic +/+ mice; P < 0.05 c.f. +/+; •P < 0.05 c.f. BMMCW/Wv).

Intrarenal Chemokine Production and Adhesion Molecule Expression in W/W^v, +/+, and BMMCW/W^v Mice with GN
Given the unchanged systemic immune responses in W/W^v mice, we explored the ability of mast cells to direct recruitment of other inflammatory cells by assessing renal expression of chemokines and adhesion molecules on day 21 after GN induction. Renal expression of chemokine mRNA LTN, RANTES, MIP-1, MIP-1, MIP-2, MCP-1, TCA-3, and IP-10 was assessed by RNAse protection assay (Table 1). We found no difference in the level of mRNA expression of any of the chemokines studied in W/W^v, +/+, or BMMCW/W^v, although IP-10 mRNA was significantly upregulated in BMMCW/W^v, potentially as a result of the elevated IFN- observed in these mice. Although these results indicate that mast cells do not participate in chemokine upregulation, it should be noted that at this time point (day 21), we may have failed to detect the role that mast cells may exert on some of the chemokines studied, as differential chemokine expression during the nephritogenic immune response in crescentic GN has been documented (42).

View larger version (82K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 6. Renal expression of intracellular adhesion molecule 1 (ICAM-1) and P-selectin in +/+, W/Wv, and BMMCW/Wv mice with GN. Expression was assessed semiquantitatively by immunofluorescence, scored 0 to 3+, and mean values observed are represented graphically. (A through C) The pattern of interstitial ICAM epifluorescence seen in +/+, W/Wv, and BMMCW/Wv mice; notice an overall reduction of interstitial ICAM expression in W/Wv mice. (D through F) The typical pattern of glomerular ICAM-1 expression in +/+, W/Wv, and BMMCW/Wv mice with GN. (G through I) Glomerular P-selectin expression was striking in +/+ and BMMCW/Wv mice with GN, whereas in W/Wv, P-selectin staining in the glomerulus was noticeably reduced (P < 0.05 c.f. +/+; •P < 0.05 c.f. BMMCW/Wv).

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

It now is generally accepted that mast cells increase in the renal fibrotic interstitium irrespective of the original pathologic process that led to the fibrotic process. A prominent rise in mast cell number has been established in a variety of renal diseases, including primary and secondary nephritis (16,19,45), acute cellular rejection of renal allografts (23), diabetic nephropathy (46), and nephrosclerosis (25). Furthermore, three patterns of mast cell localization in the kidney have been observed: (1) Mast cells localize in the interstitium contacting fibroblasts; (2) also in the interstitium, mast cells are in close contact with lymphocytes/macrophages; and (3) mast cells infiltrate the tubules (tubulitis), usually the distal tubules (25). Mast cells also have been detected in the interstitium, glomerulus, and tubules of rats that were administered a magnesium-deficient diet (47) and in murine renal lupus lesions (48). However, recent experimental studies of rat serum sickness nephritis, rat Masugi nephritis, and rat Thy1 nephritis failed to demonstrate the presence of mast cells in the kidney (25). In these studies, a standard technique for the identification of mast cells—toluidine blue staining at pH 0.5 to 5—was used. In this study, we also used this technique and failed to see any renal mast cells. However, when we used either Alcian blue/Safranin O or berberine sulfate, mast cells were revealed in the kidney, and the phenotype of the mast cells that are involved in crescentic GN were determined to be both CTMC and MMC that are present in the cortical interstitial area but not in glomeruli; in addition, tubulitis was observed. MMC were not observed in great numbers, compared with the extent of tissue infiltration by other leukocytes. This relative low mast cell frequency in diseases in which they have been shown to play an important functional role has been observed previously (49). The predominant mast cell type that we detected in the kidney was the mature CTMC identified by berberine sulfate. This observation correlates with previous human studies that showed a significantly higher density of MC_TC in forms of GN associated with fibrocellular crescents (19).

There has been considerable interest in a potential role for mast cells in the fibrotic stages of renal inflammation as they produce a number of mediators that contribute to fibrosis and collagen deposition (19). However, mast cells also produce a variety of immune regulators (cytokines and growth factors), and particularly given the demonstrated role for mast cells in other organ-specific immune disease, their role in the effector phase of inflammatory renal disease should be addressed. One recent study examined the development of autoantibody-mediated GN in systemic autoimmunity in W/W^v mice. W/W^v mice developed renal disease comparable to WT mice with immune deposits and proteinuria and with 50% exhibiting diffuse proliferative GN and 12% showing focal segmental GN (27). This model is related to immune complex disease and humoral immunity. It now is recognized that most forms of human crescentic GN are associated with Th1 predominant nephritogenic immunity and the accumulation of glomerular T cell effectors (31).

To elucidate the functional pathogenic role of mast cells in crescentic GN, we studied a well-characterized model of Th1-mediated experimental anti-GBM GN and compared the development of GN in mast cell–deficient, +/+, and BMMCW/W^v mice. Consistent with previous observations, we also found an association between mast cell numbers and interstitial inflammation. W/W^v mice were significantly protected from GN progression, with crescent formation, glomerular T cell/macrophages, and interstitial infiltrate all substantially reduced. This suggests a role for mast cells in the development of crescentic GN. When the mast cell population was re-established in W/W^v mice (BMMCW/W^v) systemic dermal (DTH), the numbers of DTH effector cells in glomeruli and disease severity were also restored to a similar severity observed in +/+ control mice, confirming that mast cells are crucial for the full manifestation of crescentic GN.

A role for mast cells in leukocyte recruitment was first established by the landmark studies of Askenase et al. (50) in dermal DTH. They demonstrated in transfer studies that Ag-specific T cells from W/W^v mice could induce DTH in mast cell–intact recipients, but Ag-specific T cells from normal mice could not induce DTH in W/W^v mice, confirming that the role of mast cells in DTH was to facilitate effector cell recruitment. These studies in GN were consistent with these results but in addition suggest a mechanism (mast cell–regulated adhesion molecule expression) for mast cell–dependent DTH effector cell recruitment. These results collectively indicate that the important subtype that must proliferate or become activated for the full development of GN is the CTMC in rodents and the MC_TC in humans. The results also indicate that mast cells mediate interstitial inflammation and that activated mast cells within the kidney synthesize mediators that participate in inflammatory cell infiltration and activation. It was surprising to note that the absence of mast cells did little to affect proteinuria but did result in reduction of serum creatinine. This observation is supported, however, by studies of secondary and primary GN in humans, in which mast cell infiltration did not correlate with urinary protein excretion but did with serum concentration of creatinine at the time of renal biopsy (16). In conclusion, this study demonstrates that interstitial mast cells modify the behaviors of adjacent kidney cells that amplify mast cell signals by releasing other soluble mediators (51), i.e., adhesion molecule expression, and thus promoting the inflammatory cascade and renal damage.

	Acknowledgments

 
These studies were funded by a program grant from the National Health and Medical Research Council of Australia. J.R.T. was awarded a Faculty of Medicine Fellowship to conduct these studies.

The technical assistance of Alice Wright, Dr. Ming Li, Amanda Ruth, Kristy Edgtton, and Dragana Moussa is gratefully acknowledged.

	Footnotes

 
Published online ahead of print. Publication date available at www.jasn.org.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Boyce JA: Mast cells: Beyond IgE. J Allergy Clin Immunol111 :24 –32,2003[CrossRef][Medline]
2. Welle M: Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase. J Leukoc Biol61 :233 –245,1997[Abstract]
3. Grodzki AC, Pastor MV, Sousa JF, Oliver C, Jamur MC: Differential expression of integrin subunits on adherent and nonadherent mast cells. Braz J Med Biol Res36 :1101 –1109,2003[Medline]
4. Kambe N, Hiramatsu H, Shimonaka M, Fujino H, Nishikomori R, Heike T, Ito M, Kobayashi K, Ueyama Y, Matsuyoshi N, Miyachi Y, Nakahata T: Development of both human connective tissue-type and mucosal-type mast cells in mice from hematopoietic stem cells with identical distribution pattern to human body. Blood103 :860 –867,2004[Abstract/Free Full Text]
5. Metcalfe DD, Baram D, Mekori YA: Mast cells. Physiol Rev77 :1033 –1079,1997[Abstract/Free Full Text]
6. Vliagoftis H: Thrombin induces mast cell adhesion to fibronectin: Evidence for involvement of protease-activated receptor-1. J Immunol169 :4551 –4558,2002[Abstract/Free Full Text]
7. Gelli SJ, Wershil B: The two faces of the mast cell. Nature381 :21 –22,1996[CrossRef][Medline]
8. Biedermann T, Kneilling M, Mailhammer R, Maier K, Sander CA, Kollias G, Kunkel SL, Hultner L, Rocken M: Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med192 :1441 –1452,2000[Abstract/Free Full Text]
9. Robbie-Ryan M, Brown MA: The role of mast cells in allergy and autoimmunity. Curr Opin Immunol14 :728 –733,2002[CrossRef][Medline]
10. Secor VH, Secor WE, Gutekunst CA, Brown MA: Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med191 :813 –822,2000[Abstract/Free Full Text]
11. Johnston B, Burns AR, Kubes P: A role for mast cells in the development of adjuvant-induced vasculitis and arthritis. Am J Pathol152 :555 –563,1998[Abstract]
12. Kobayashi T, Miura T, Haba T, Sato M, Serizawa I, Nagai H, Ishizaka K: An essential role of mast cells in the development of airway hyperresponsiveness in a murine asthma model. J Immunol164 :3855 –3861,2000[Abstract/Free Full Text]
13. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB: Mast cells: A cellular link between autoantibodies and inflammatory arthritis. Science297 :1689 –1692,2002[Abstract/Free Full Text]
14. El-Koraie AF, Baddour NM, Adam AG, El Kashef EH, El Nahas AM: Role of stem cell factor and mast cells in the progression of chronic glomerulonephritides. Kidney Int60 :167 –172,2001[CrossRef][Medline]
15. Kondo S, Kagami S, Kido H, Strutz F, Muller GA, Kuroda Y: Role of mast cell tryptase in renal interstitial fibrosis. J Am Soc Nephrol12 :1668 –1676,2001[Abstract/Free Full Text]
16. Hiromura K, Kurosawa M, Yano S, Naruse T: Tubulointerstitial mast cell infiltration in glomerulonephritis. Am J Kidney Dis32 :593 –599,1998[Medline]
17. Roberts IS, Brenchley PE: Mast cells: The forgotten cells of renal fibrosis. J Clin Pathol53 :858 –862,2000[Abstract/Free Full Text]
18. El Kossi MM, El Nahas AM: Stem cell factor and crescentic glomerulonephritis. Am J Kidney Dis41 :785 –795,2003[Medline]
19. Toth T, Toth-Jakatics R, Jimi S, Ihara M, Urata H, Takebayashi S: Mast cells in rapidly progressive glomerulonephritis. J Am Soc Nephrol10 :1498 –1505,1999[Abstract/Free Full Text]
20. Kitching AR, Tipping PG, Huang XR, Mutch DA, Holdsworth SR: Interleukin-4 and interleukin-10 attenuate established crescentic glomerulonephritis in mice. Kidney Int52 :52 –59,1997[Medline]
21. Kitching AR, Tipping PG, Mutch DA, Huang XR, Holdsworth SR: Interleukin-4 deficiency enhances Th1 responses and crescentic glomerulonephritis in mice. Kidney Int53 :112 –118,1998[CrossRef][Medline]
22. Timoshanko JR, Sedgwick JD, Holdsworth SR, Tipping PG: Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentic glomerulonephritis. J Am Soc Nephrol14 :1785 –1793,2003[Abstract/Free Full Text]
23. Lajoie G, Nadasdy T, Laszik Z, Blick KE, Silva FG: Mast cells in acute cellular rejection of human renal allografts. Mod Pathol9 :1118 –1125,1996[Medline]
24. Ehara T, Shigematsu H: Contribution of mast cells to the tubulointerstitial lesions in IgA nephritis. Kidney Int54 :1675 –1683,1998[CrossRef][Medline]
25. Ehara T, Shigematsu H: Mast cells in the kidney. Nephrology (Carlton)8 :130 –138,2003[Medline]
26. Jones SE, Kelly DJ, Cox AJ, Zhang Y, Gow RM, Gilbert RE: Mast cell infiltration and chemokine expression in progressive renal disease. Kidney Int64 :906 –913,2003[CrossRef][Medline]
27. Lin L, Gerth AJ, Peng SL: Susceptibility of mast cell-deficient W/Wv mice to pristane-induced experimental lupus nephritis. Immunol Lett91 :93 –97,2004[CrossRef][Medline]
28. Miyazawa S, Hotta O, Doi N, Natori Y, Nishikawa K: Role of mast cells in the development of renal fibrosis: Use of mast cell-deficient rats. Kidney Int65 :2228 –2237,2004[CrossRef][Medline]
29. Rennke HG, Klein PS, Sandstrom DJ, Mendrick DL: Cell-mediated immune injury in the kidney: Acute nephritis induced in the rat by azobenzenearsonate. Kidney Int45 :1044 –1056,1994[Medline]
30. Huang XR, Tipping PG, Shuo L, Holdsworth SR: Th1 responsiveness to nephritogenic antigens determines susceptibility to crescentic glomerulonephritis in mice. Kidney Int51 :94 –103,1997[Medline]
31. Kitching AR, Holdsworth SR, Tipping PG: Crescentic glomerulonephritis—A manifestation of a nephritogenic Th1 response? Histol Histopathol15 :993 –1003,2000[Medline]
32. Tipping PG, Kitching AR, Holdsworth SR: The formation of glomerular crescents. In: Immunologic Renal Diseases, 2nd Ed., edited by Neilson EG, Couser WG, Philadelphia, Lippincott Williams & Wilkins,2001 , pp633 –656
33. Tanzola MB, Robbie-Ryan M, Gutekunst CA, Brown MA: Mast cells exert effects outside the central nervous system to influence experimental allergic encephalomyelitis disease course. J Immunol171 :4385 –4391,2003[Abstract/Free Full Text]
34. von Ruden T, Kandels S, Radaszkiewicz T, Ullrich A, Wagner EF: Development of a lethal mast cell disease in mice reconstituted with bone marrow cells expressing the v-erbB oncogene. Blood79 :3145 –3158,1992[Abstract/Free Full Text]
35. Kitching AR, Ru Huang X, Turner AL, Tipping PG, Dunn AR, Holdsworth SR: The requirement for granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in leukocyte-mediated immune glomerular injury. J Am Soc Nephrol13 :350 –358,2002[Abstract/Free Full Text]
36. Kitching AR, Holdsworth SR, Tipping PG: IFN-gamma mediates crescent formation and cell-mediated immune injury in murine glomerulonephritis. J Am Soc Nephrol10 :752 –759,1999[Abstract/Free Full Text]
37. Ruth AJ, Kitching AR, Semple TJ, Tipping PG, Holdsworth SR: Intrinsic renal cell expression of CD40 directs Th1 effectors inducing experimental crescentic glomerulonephritis. J Am Soc Nephrol14 :2813 –2822,2003[Abstract/Free Full Text]
38. Tipping PG, Kitching AR, Huang XR, Mutch DA, Holdsworth SR: Immune modulation with interleukin-4 and interleukin-10 prevents crescent formation and glomerular injury in experimental glomerulonephritis. Eur J Immunol27 :530 –537,1997[Medline]
39. Huang XR, Holdsworth SR, Tipping PG: Evidence for delayed-type hypersensitivity mechanisms in glomerular crescent formation. Kidney Int46 :69 –78,1994[Medline]
40. Timoshanko JR, Kitching AR, Iwakura Y, Holdsworth SR, Tipping PG: Contributions of IL-1beta and IL-1alpha to crescentic glomerulonephritis in mice. J Am Soc Nephrol15 :910 –918,2004[Abstract/Free Full Text]
41. Kitamura Y: Heterogeneity of mast cells and phenotypic change between subpopulations. Annu Rev Immunol7 :59 –76,1989[Medline]
42. Natori Y, Sekiguchi M, Ou Z, Natori Y: Gene expression of CC chemokines in experimental crescentic glomerulonephritis (CGN). Clin Exp Immunol1 :143 –148,1997
43. Marshall JS: Mast-cell responses to pathogens. Nat Rev Immunol4 :787 –799,2004[CrossRef][Medline]
44. Frossi B, De Carli M, Pucillo C: The mast cell: An antenna of the microenvironment that directs the immune response. J Leukoc Biol75 :579 –585,2004[Abstract/Free Full Text]
45. Otsubo S, Nitta K, Uchida K, Yumura W, Nihei H: Mast cells and tubulointerstitial fibrosis in patients with ANCA-associated glomerulonephritis. Clin Exp Nephrol7 :41 –47,2003[CrossRef][Medline]
46. Ruger BM, Hasan Q, Greenhill NS, Davis PF, Dunbar PR, Neale TJ: Mast cells and type VIII collagen in human diabetic nephropathy. Diabetologia39 :1215 –1222,1996[Medline]
47. Veilleux R: Mast cell increase in the duodenum and kidney of magnesium-deficient rats. Lab Invest33 :80 –87,1975[Medline]
48. Ohmori J: A study of mast cells in autoimmune mice: The proliferative response of autoimmune mast cells to cytokines. Autoimmunity17 :279 –285,1994[Medline]
49. Brown MA, Tanzola MB, Robbie-Ryan M: Mechanisms underlying mast cell influence on EAE disease course. Mol Immunol38 :1373 –1378,2001[CrossRef]
50. Askenase PW, Van Loveren H, Kraeuter-Kops S, Ron Y, Meade R, Theoharides TC, Nordlund JJ, Scovern H, Gerhson MD, Ptak W: Defective elicitation of delayed-type hypersensitivity in W/Wv and SI/SId mast cell-deficient mice. J Immunol131 :2687 –2694,1983[Abstract]
51. Wolters PJ, Mallen-St Clair J, Lewis CC, Villalta SA, Baluk P, Erle DJ, Caughey GH: Tissue-selective mast cell reconstitution and differential lung gene expression in mast cell-deficient Kit(W-sh)/Kit(W-sh) sash mice. Clin Exp Allergy35 :82 –88,2005[CrossRef][Medline]

This article has been cited by other articles:

				S. R. Holdsworth and S. A. Summers Role of Mast Cells in Progressive Renal Diseases J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2254 - 2261. [Abstract] [Full Text] [PDF]

				V. W. S. Lee, Y. M. Wang, Y. P. Wang, D. Zheng, T. Polhill, Q. Cao, H. Wu, I. E. Alexander, S. I. Alexander, and D. C. H. Harris Regulatory immune cells in kidney disease Am J Physiol Renal Physiol, August 1, 2008; 295(2): F335 - F342. [Abstract] [Full Text] [PDF]

				P. Boor, K. Sebekova, T. Ostendorf, and J. Floege Treatment targets in renal fibrosis Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407. [Full Text] [PDF]

				A.-J. Ruth, A. R. Kitching, R. Y.Q. Kwan, D. Odobasic, J. D.K. Ooi, J. R. Timoshanko, M. J. Hickey, and S. R. Holdsworth Anti-Neutrophil Cytoplasmic Antibodies and Effector CD4+ Cells Play Nonredundant Roles in Anti-Myeloperoxidase Crescentic Glomerulonephritis J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1940 - 1949. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: ASN.2005080799v1 17/1/150    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Timoshanko, J. R. Articles by Holdsworth, S. R. Search for Related Content PubMed PubMed Citation Articles by Timoshanko, J. R. Articles by Holdsworth, S. R.